

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6653198

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
ROCKET PHARMACEUTICALS, LTD.		02/03/2021
RECEIVING PARTY DATA		
Name:	SPACECRAFT SEVEN, LLC	
Street Address:	9 CEDAR BROOK DRIVE	
City:	CRANBURY	
State/Country:	NEW JERSEY	
Postal Code:	08512	
PROPERTY NUMBERS Total: 15		
Property Type	Number	
Application Number:	62852216	
PCT Number:	US2020034394	
Application Number:	62656292	
PCT Number:	US2019027083	
PCT Number:	US2019029744	
Application Number:	62712146	
PCT Number:	US2019044237	
Application Number:	62697302	
Patent Number:	10703797	
PCT Number:	US2019041465	
Application Number:	62765112	
PCT Number:	US2019046890	
Application Number:	62804521	
Application Number:	62934928	
PCT Number:	US2020017987	
CORRESPONDENCE DATA		
Fax Number:	(202)842-7899	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2064528700	

Email:	sclingerman@cooley.com, zPatDCDocketing@cooley.com
Correspondent Name:	COOLEY LLP
Address Line 1:	1299 PENNSYLVANIA AVE, NW, SUITE 700
Address Line 2:	ATTN: PATENT DEPT / CAROL D. LAHERTY
Address Line 4:	WASHINGTON, D.C. 20004

ATTORNEY DOCKET NUMBER:	ROPA-2000
NAME OF SUBMITTER:	CAROL D. LAHERTY
SIGNATURE:	/Carol D.Laherty/
DATE SIGNED:	04/13/2021

Total Attachments: 7

source=Rocket Ltd to Spacecraft Seven#page1.tif
source=Rocket Ltd to Spacecraft Seven#page2.tif
source=Rocket Ltd to Spacecraft Seven#page3.tif
source=Rocket Ltd to Spacecraft Seven#page4.tif
source=Rocket Ltd to Spacecraft Seven#page5.tif
source=Rocket Ltd to Spacecraft Seven#page6.tif
source=Rocket Ltd to Spacecraft Seven#page7.tif

**ASSIGNMENT OF PATENT RIGHTS
(Company to Company)**

Rocket Pharmaceuticals, Ltd., a corporation having its principal place of business at The Empire State Building, 350 Fifth Avenue, Suite 7530, New York, New York 10118, US (herein referred to as "Assignor") owns the entire right, title and interest in any Letters Patent(s) ("said patent(s)") and any Patent application(s) ("said application(s)") set forth in the attached listing, as well as any invention(s) ("said invention(s)") disclosed in said application(s) and said patent(s).

WHEREAS, Spacecraft Seven, LLC, a limited liability company having its principal place of business at 9 Cedar Brook Drive, Cranbury, New Jersey 08512, US, its successors, legal representatives and assigns (the "Assignee"), is desirous of acquiring the entire right, title, and interest in and to said invention(s), said application(s), and said patent(s), the right to file applications on said invention(s), the entire right, title and interest in and to any application(s), the right to recover any and all past, present, and future damages, including provisional or other royalties, for any and all past, present, and future infringements of said application(s) and said patent(s), and the entire right, title, and interest in and to any and all Letters Patent or Patents, United States or foreign, to be obtained for said invention(s) and said application(s);

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns the entire right, title, and interest in and to said invention(s), and application(s), and said patent(s), the right to file applications on said invention(s), the entire right, title and interest in and to any applications for Letters Patent of the United States or other countries claiming priority to said application(s), including divisions, continuations, and continuations-in-part of said application(s), the right to recover any and all past, present, and future damages, including provisional or other royalties, for any and all past, present, and future infringements of said application(s) and said patent(s), the entire right, title and interest in and to any and all Letters Patent or Patents, United States or foreign, to be obtained for said invention(s) and said application(s), the entire right, title and interest in and to any and all reissues and extensions of said patent(s), and all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, the Assignor is the sole and lawful owner of the entire right, title and interest in and to said invention(s), said application(s), and said

patent(s), and that the same are unencumbered, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth;


AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said invention(s), said application(s), said patent(s), any application claiming priority to said application(s), any reissue or extension of said patent(s), and any United States or foreign Letters Patent or Patents for said invention(s) or said application(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.), is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said invention(s), without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignor hereby requests the Commissioner of Patents to issue any and all aforementioned patent(s) of the United States to the Assignee, as the Assignee of said invention(s) and the Letters Patent to be issued thereon for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Assignor(s) and Assignee(s) understand that electronic signatures are acceptable and that, by signing electronically, signatories agree to the use of electronic signatures.


For and on behalf of ASSIGNOR:

Date: 2/3/2021

By: 
Name: Gaurav Shah
Title: CEO
Company: Rocket Pharmaceuticals,
Ltd.

For and on behalf of ASSIGNEE:

Date: 2/3/2021

By: 
Name: Gaurav Shah
Title: CEO
Company: Spacecraft Seven, LLC

Cooley Docket No.	Title/Mark	Application No.	Application Date	Registration No.	Registration Date	Case Status	Country	Description
ROPA-003/00US 329592-2006	GENE THERAPY VECTORS FOR INFANTILE MALIGNANT OSTEOPETROSIS	62/852,216	5/23/2019			Expired	United States of America	Provisional
ROPA-003/01WO 329592-2098	GENE THERAPY VECTORS FOR INFANTILE MALIGNANT OSTEOPETROSIS	PCT/US2020/034394	5/22/2020			Published	Patent Cooperation Treaty	National
ROPA-008/00US 329592-2018	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	62/656,292	4/11/2018			Expired	United States of America	Provisional
ROPA-008/01AU 329592-2105	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	2019252662	4/11/2019			Application Filed	Australia	PCT National Phase
ROPA-008/01BR 329592-2106	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	BR1120200208418	4/11/2019			Application Filed	Brazil	PCT National Phase
ROPA-008/01CA 329592-2107	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	3093708	4/11/2019			Application Filed	Canada	PCT National Phase
ROPA-008/01CN 329592-2108	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	201980018070.0	4/11/2019			Published	China	PCT National Phase
ROPA-008/01EP 329592-2109	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	19785212.2	4/11/2019			Published	European Patent Office	PCT National Phase
ROPA-008/01IL 329592-2111	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	277878	4/11/2019			Application Filed	Israel	PCT National Phase
ROPA-008/01IN 329592-2110	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	202017039217	4/11/2019			Application Filed	India	PCT National Phase
ROPA-008/01JP 329592-2112	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	2020-555511	4/11/2019			Application Filed	Japan	PCT National Phase
ROPA-008/01KR 329592-2113	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	10-2020-7028804	4/11/2019			Application Filed	Republic of Korea	PCT National Phase
ROPA-008/01MX 329592-2114	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	MX/a/2020/010718	4/11/2019			Application Filed	Mexico	PCT National Phase
ROPA-008/01RU 329592-2115	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	2020129103	4/11/2019			Application Filed	Russian Federation	PCT National Phase
ROPA-008/01SG 329592-2116	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	11202008400S	4/11/2019			Application Filed	Singapore	Normal via PCT National Phase
ROPA-008/01US 329592-2118	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	17/045,383	4/11/2019			Application Filed	United States of America	PCT National Phase
ROPA-008/01WO 329592-2068	COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT	PCT/US2019/027083	4/11/2019			Expired/PC T Period Over	Patent Cooperation Treaty	National
ROPA-009/00US 329592-2020	GENE THERAPY FOR CNS DEGENERATION	62/664,006	4/27/2018			Expired	United States of America	Provisional
ROPA-009/01AU 329592-2119	GENE THERAPY FOR CNS DEGENERATION	2019261646	4/29/2019			Application Filed	Australia	PCT National Phase
ROPA-009/01BR 329592-2120	GENE THERAPY FOR CNS DEGENERATION	BR1120200219037	4/29/2019			Application Filed	Brazil	PCT National Phase
ROPA-009/01CA 329592-2121	GENE THERAPY FOR CNS DEGENERATION	3096293	4/29/2019			Application Filed	Canada	PCT National Phase
ROPA-009/01CN 329592-2122	GENE THERAPY FOR CNS DEGENERATION	201980028117.1	4/29/2019			Application Filed	China	PCT National Phase
ROPA-009/01EP 329592-2123	GENE THERAPY FOR CNS DEGENERATION	19792202.4	4/29/2019			Exam Requested	European Patent Office	PCT National Phase

ROPA-009/01IL 329592-2125	GENE THERAPY FOR CNS DEGENERATION	278213	4/29/2019			Application Filed	Israel	PCT National Phase
ROPA-009/01IN 329592-2124	GENE THERAPY FOR CNS DEGENERATION	202017045888	4/29/2019			Application Filed	India	PCT National Phase
ROPA-009/01JP 329592-2126	GENE THERAPY FOR CNS DEGENERATION	2020-560275	4/29/2019			Application Filed	Japan	PCT National Phase
ROPA-009/01KR 329592-2127	GENE THERAPY FOR CNS DEGENERATION	10-2020-7033123	4/29/2019			Application Filed	Republic of Korea	PCT National Phase
ROPA-009/01MX 329592-2128	GENE THERAPY FOR CNS DEGENERATION	MX/a/2020/011386	4/29/2019			Application Filed	Mexico	PCT National Phase
ROPA-009/01RU 329592-2129	GENE THERAPY FOR CNS DEGENERATION	2020134965	4/29/2019			Response Filed	Russian Federation	PCT National Phase
ROPA-009/01SG 329592-2130	GENE THERAPY FOR CNS DEGENERATION	11202010061P	4/29/2019			Application Filed	Singapore	Normal via PCT National Phase
ROPA-009/01US 329592-2132	GENE THERAPY FOR CNS DEGENERATION	17/050,784	4/29/2019			Application Filed	United States of America	PCT National Phase
ROPA-009/01WO 329592-2067	GENE THERAPY FOR CNS DEGENERATION	PCT/US2019/029744	4/29/2019			Expired/PC T Period Over	Patent Cooperation Treaty	National
ROPA-010/00US 329592-2031	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	62/712,146	7/30/2018			Expired	United States of America	Provisional
ROPA-010/01AU 329592-2179	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	TBD	7/30/2019			Application Filed	Australia	PCT National Phase
ROPA-010/01BR 329592-2180	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	TBD	7/30/2019			To be filed	Brazil	PCT National Phase
ROPA-010/01CA 329592-2181	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	TBD	7/30/2019			Application Filed	Canada	PCT National Phase
ROPA-010/01CN 329592-2182	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	TBD	7/30/2019			To be filed	China	PCT National Phase
ROPA-010/01EP 329592-2183	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	19844952.2	7/30/2019			To be filed	European Patent Office	PCT National Phase
ROPA-010/01IL 329592-2185	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	TBD	7/30/2019			To be filed	Israel	PCT National Phase
ROPA-010/01IN 329592-2184	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	TBD	7/30/2019			To be filed	India	PCT National Phase
ROPA-010/01JP 329592-2186	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	TBD	7/30/2019			To be filed	Japan	PCT National Phase
ROPA-010/01KR 329592-2187	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	TBD	7/30/2019			To be filed	Republic of Korea	PCT National Phase
ROPA-010/01MX 329592-2188	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	TBD	7/30/2019			To be filed	Mexico	PCT National Phase
ROPA-010/01RU 329592-2189	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	2021101135	7/30/2019			Application Filed	Russian Federation	PCT National Phase
ROPA-010/01SG 329592-2190	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	11202100025Q	7/30/2019			Application Filed	Singapore	Normal via PCT National Phase
ROPA-010/01US 329592-2191	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	TBD	7/30/2019			To be filed	United States of America	PCT National Phase

ROPA-010/01WO 329592-2074	METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS	PCT/US2019/044237	7/30/2019			Published	Patent Cooperation Treaty	National
ROPA-011/00US 329592-2032	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	62/697,302	7/12/2018			Expired	United States of America	Provisional
ROPA-011/01AU 329592-2195	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	TBD	7/11/2019			Application Filed	Australia	PCT National Phase
ROPA-011/01BR 329592-2196	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	BR112021000509	7/11/2019			Application Filed	Brazil	PCT National Phase
ROPA-011/01CA 329592-2197	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	TBD	7/11/2019			Application Filed	Canada	PCT National Phase
ROPA-011/01CN 329592-2198	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	TBD	7/11/2019			To be filed	China	PCT National Phase
ROPA-011/01EP 329592-2199	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	19835189.2	7/11/2019			To be filed	European Patent Office	PCT National Phase
ROPA-011/01IL 329592-2200	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	279918	7/11/2019			Application Filed	Israel	PCT National Phase
ROPA-011/01IN 329592-2201	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	202117001214	7/11/2019			Application Filed	India	PCT National Phase
ROPA-011/01JP 329592-2202	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	2021-500664	7/11/2019			Application Filed	Japan	PCT National Phase
ROPA-011/01KR 329592-2203	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	TBD	7/11/2019			To be filed	Republic of Korea	PCT National Phase
ROPA-011/01MX 329592-2204	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	MX/a/2021/000443	7/11/2019			Application Filed	Mexico	PCT National Phase
ROPA-011/01RU 329592-2205	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	TBD	7/11/2019			To be filed	Russian Federation	PCT National Phase
ROPA-011/01SG 329592-2206	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	11202100022S	7/11/2019			Application Filed	Singapore	Normal via PCT National Phase
ROPA-011/01US 329592-2081	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	16/729,002	12/27/2019	10,703,797	7/7/2020	Registered	United States of America	Continuation
ROPA-011/01WO 329592-2071	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	PCT/US2019/041465	7/11/2019			Published	Patent Cooperation Treaty	National
ROPA-011/02US 329592-2071	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	17/144,933	1/8/2021			Application Filed	United States of America	Continuation
ROPA-012/00US 329592-2033	PRODUCTION METHODS FOR VIRAL VECTORS	62/765,112	8/16/2018			Expired	United States of America	Provisional
ROPA-012/01AU 329592-2208	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	Australia	PCT National Phase
ROPA-012/01CA 329592-2210	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	Canada	PCT National Phase
ROPA-012/01CN 329592-2211	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	China	PCT National Phase
ROPA-012/01EP 329592-2212	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	European Patent Office	PCT National Phase
ROPA-012/01IL 329592-2214	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	Israel	PCT National Phase

ROPA-012/01IN 329592-2213	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	India	PCT National Phase
ROPA-012/01JP 329592-2215	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	Japan	PCT National Phase
ROPA-012/01KR 329592-2216	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	Republic of Korea	PCT National Phase
ROPA-012/01MX 329592-2217	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	Mexico	PCT National Phase
ROPA-012/01RU 329592-2218	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	Russian Federation	PCT National Phase
ROPA-012/01SG 329592-2219	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	Singapore	Normal via PCT National Phase
ROPA-012/01US 329592-2220	PRODUCTION METHODS FOR VIRAL VECTORS	TBD	8/16/2019			To be filed	United States of America	PCT National Phase
ROPA-012/01WO 329592-2075	PRODUCTION METHODS FOR VIRAL VECTORS	PCT/US2019/046890	8/16/2019			Published	Patent Cooperation Treaty	National
ROPA-013/00US 329592-2053	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	62/804,521	2/12/2019			Expired	United States of America	Provisional
ROPA-013/01US 329592-2079	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	62/934,928	11/13/2019			Expired	United States of America	Provisional
ROPA-013/02WO 329592-2080	GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE	PCT/US2020/017987	2/12/2020			Published	Patent Cooperation Treaty	National
ROPA-016/00US 329592-2099	AAV VIRION EXPRESSING ACTIVATED PARKIN	63/027,866	5/20/2020			Application Filed	United States of America	Provisional
ROPA-017/00US 329592-2100	MITOCHONDRIAL TARGETING SEQUENCE- PARKIN FUSIONS AND USES THEREOF	63/027,868	5/20/2020			Application Filed	United States of America	Provisional
ROPA-018/00US 329592-2101	ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF	63/061,726	8/5/2020			Application Filed	United States of America	Provisional
ROPA-020/00US 329592-2134	CSRP3 (CYSTEINE AND GLYCINE RICH PROTEIN 3) GENE THERAPY	63/061,727	8/5/2020			Application Filed	United States of America	Provisional
ROPA-021/00US 329592-2135	PLAKOPHILIN-2 (PKP2) GENE THERAPY USING AAV VECTOR	63/063,032	8/7/2020			Application Filed	United States of America	Provisional